Study title:
Asakura M, Ikegame K, Yoshihara S,Taniguchi S, Mori T, Etoh T, Takami A, Yoshida T, Fukuda T, Hatanaka K, Kanamori H, Yujiri T, Atsuta Y, Sakamaki H, Suzuki R, Ogawa H. 2010. Use of foscarnet for
cytomegalovirus infection after
allogeneic hematopoietic stem cell
transplantation from a related
donor. Int J Hematol. 2010
Sep;92(2):351-9.Asakura M, Ikegame K, Yoshihara S,Taniguchi S, Mori T, Etoh T, Takami A, Yoshida T, Fukuda T, Hatanaka K, Kanamori H, Yujiri T, Atsuta Y, Sakamaki H, Suzuki R, Ogawa H. 2010. Use of foscarnet for
cytomegalovirus infection after
allogeneic hematopoietic stem cell
transplantation from a related
donor. Int J Hematol. 2010
Sep;92(2):351-9.
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Virus Diseases [C02]
|
Brands: Please see report, Please see report |
MAH holders: Please see report |
Assessment: |
Active substance: FOSCARNET |
ATC code: |
Document link:
Asakura M et al 2010.pdf
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: Review Article |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
-
|
Y
|